Forget Pfizer — Medicine's Golden Age Is Here!

Explosive change is coming and so are even more explosive gains... Explosive change is coming and so are even more explosive gains... Energy and Capital: Practical Investment Analysis in the new Energy Economy [Energy and Capital logo] Forget Pfizer — Medicine's Golden Age Is Here! By Keith Kohl | October 16, 2021 - Baltimore, MD Experts are calling it the Industrial Revolution for health care... And Moore’s law for medicine.The massive wave of innovation occurring throughout the sector is the dawn of medicine’s “Golden Age.”And the COVID-19 vaccines that were created in record time are just the start.What’s coming down the pike is going to be much, much bigger.According to Barron’s, "Explosive change is coming in our ability to diagnose, treat, and even cure many debilitating diseases." With a record number of investments pouring into this sector...And the biotech industry and the government working together more closely than they ever have before... We’re seeing the explosive convergence and optimization of a number of different technologies that will allow us to cure many diseases. Lifesaving medicines and treatments could get to patients much faster — and much more cheaply.We could even witness the cure for cancer... or even the cure for ALL diseases. This is why biotech is going to be the hottest place for investors to be in 2022. If you had been investing in this sector over the past year... You could have cashed in on all these huge gains: - +1,273% - +1,144% - +982% - +460% - +350% A $2,500 investment into each of those plays would have handed you $105,225 in pure profit.But I think biotech’s “Golden Age” is going to put those gains to shame.We are witnessing the "Industrial Revolution" in biotech...And it’s all starting right now. In short, if you stay OUT of the biotech market, you WILL miss life-changing gains.We’re talking about more new innovations, drugs, and therapies than ever before...That could set you up to potentially clock [massive paydays of $16,890, $43,460, and even $193,800...]( From the most lucrative and fast-paying biotech stocks in the world. And I’m not talking about multibillion-dollar giants like Pfizer, Johnson & Johnson, or Merck... But the smaller, innovative companies that are not covered by the mainstream press... The billion-dollar buyout targets for these massive, cash-rich pharmaceutical giants. [Take advantage of this now.]( To your wealth, [Keith Kohl sig]Keith KohlInvestment Director, Topline Trader --------------------------------------------------------------- This email was sent to {EMAIL}. It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, you may [unsubscribe here](, and view our privacy policy and information on how to manage your subscription. To ensure that you receive future issues of Energy and Capital, please add newsletter@energyandcapital.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance. Energy and Capital, Copyright © 2021, Angel Publishing LLC. All rights reserved. 3 E Read Street, Baltimore, MD 21202. Your privacy is important to us – we will never rent or sell your e-mail or personal information. Please read our [Privacy Policy](. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment advice. Read our [Details and Disclosures.](